R01

Over $3.7 million in NIH grants will fund research on impacts of climate change on HIV-related health outcomes

Retrieved on: 
Wednesday, October 18, 2023
WHO, CUNY, Research, UCSB, Graduate Center, CUNY, National Institute of Allergy and Infectious Diseases, Weather, UCSF, Temperature, Population health, Health, Health equity, Science, Public health, Global Climate and Health Alliance, Implementation Science, Climate, NIAID, Icahn School of Medicine at Mount Sinai, HIV, Diabetes, Food, R01, University, Geographic Locator Codes, PEPFAR, Medicine, Risk, HIV/AIDS, Hypertension, Mount Sinai, Health policy, NIH, SIG, Climate change, Area studies, UNAIDS, Drug resistance, Infection, Epidemiology, Pharmaceutical industry, Agriculture, Central Africa

"These climate-related factors likely also increase the risk of poor clinical outcomes among people living with HIV."

Key Points: 
  • "These climate-related factors likely also increase the risk of poor clinical outcomes among people living with HIV."
  • Work on the four-year R01 award will combine data sources uniquely suited to characterize the influence of extreme weather on HIV care outcomes.
  • This, in turn, can inform strategies to help mitigate the impacts of climate change and extreme weather on HIV care outcomes and the trajectory of the HIV pandemic.
  • The team is currently recruiting for a full-time Postdoctoral Fellow to focus on climate and health research, as well as a full-time Project Manager , to join the project team.

Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections

Retrieved on: 
Thursday, October 5, 2023
Patent, Partnership, Klebsiella pneumoniae, Infection, Methicillin-resistant Staphylococcus aureus, Homeland, Homeland security, Innovation, Acinetobacter baumannii, IND, Fungus, National Institute of Allergy and Infectious Diseases, Fungal infection, Hulk, Laboratory, Pseudomonas aeruginosa, Patient, FDA, Mucormycosis, R01, Macrophage, Escherichia coli, Immune system, USC, Bangladesh Technical Education Board, Vancomycin-resistant Enterococcus, ESBL, Korea Disease Control and Prevention Agency, Blood, Enterococcus, Translational medicine, Denise Spellberg, NIH, Vaccine, Pharmaceutical industry, Klebsiella, Science

Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.

Key Points: 
  • Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.
  • Early data suggest that a second dose may extend the window to prevent infection.
  • The study was published in Science and Translational Medicine.
  • These infections are often caused by highly antibiotic-resistant superbugs, many of which are targeted by this new ExBaq vaccine.

Lundquist Investigator Dr. Harry Rossiter Awarded $3.8 Million NIH Grant To Develop the Next-Generation Cardiopulmonary Exercise Test

Retrieved on: 
Wednesday, September 20, 2023
Exercise, Heart, David Geffen School of Medicine at UCLA, TLI, R01, Research, Doctor of Philosophy, Bangladesh Technical Education Board, Athlete, Gold, Patient, 4-HO-McPeT, CPET, UCLA, Harbor–UCLA Medical Center, NIH, Disease, Medical device, Medicine

The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.

Key Points: 
  • The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.
  • Dr. Rossiter’s research team at TLI has developed the next generation of the cardiopulmonary exercise test; the standard clinical test to investigate exercise intolerance.
  • “This research builds on what Lundquist Institute investigators developed fifty years ago,” said David I. Meyer, TLI President and CEO.
  • “This next-generation CPET being developed by Dr. Rossiter and his team will become the new gold standard for clinical investigation of exercise intolerance.”

City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

Retrieved on: 
Tuesday, August 1, 2023
Linda, Molecule, Alex's Lemonade Stand Foundation, DNA, Rituximab, Insulin, Human, City of Hope National Medical Center, City of Hope, R01, Neoplasm, Biotechnology, Cell Chemical Biology, Trastuzumab, Clinical trial, Ovary, Breast, Toxicity, Brain, Research, Gene expression, Prostate, Treatment of lung cancer, Cell, Molecular diagnostics, Translational Genomics Research Institute, Cetuximab, Experiment, RLL, Bangladesh Technical Education Board, DNA replication, National Cancer Institute, S phase, Australian Melanoma Research Foundation, Patient, Department of Defense Serum Repository, Apoptosis, LOS, Beckman Research Institute, Proliferating cell nuclear antigen, Therapy, Skin, PCNA, Vaccine, Pharmaceutical industry, Molecular oncology, City, Hope

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. As the scientists continue to investigate the foundational mechanisms that make this cancer-stopping pill work in animal models, they note that there is an ongoing Phase 1 clinical trial testing the City of Hope-developed therapeutic in humans.

Key Points: 
  • Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.
  • The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope."
  • Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines."
  • "City of Hope has world leaders in cancer research.

Arcade Therapeutics and UT Austin Jointly Announce a $3.8M NIMH Grant to Fund Large Clinical Trial Testing the Efficacy of ABM-02, The First Game-Based Digital Therapeutic for Major Depressive Disorder

Retrieved on: 
Wednesday, July 26, 2023
Arcade, Depression, University, R01, Clinical trial, Mental Health Research Institute (Melbourne), Mental health, DSM-IV codes, NIMH, National Institute of Mental Health, Trial of the century, ABM, MDD, 1996-10-24 Frank Erwin Center, University of Texas, Austin, TX, Patient, University of Texas at Austin, Entrepreneurship, Principal, FDA, Therapy, News, National Institute for Health and Care Excellence, Pharmaceutical industry, Psychology, Center for Transportation Research UT Austin

NEW YORK, July 26, 2023 /PRNewswire/ -- Arcade Therapeutics, a leading developer of game-based therapies for mental health, and University of Texas Austin's Institute for Mental Health Research, a leading research center in the field of depression, jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD).

Key Points: 
  • The study will assess 600 participants suffering from depression across these three, randomly-assigned arms, and will be the largest and most rigorous test of ABM for depression ever completed.
  • Arcade intends to use findings from this ambitious clinical study to support their FDA submission of ABM-02 as the first game-based treatment for Major Depressive Disorder.
  • This news follows the recent success of a clinical trial investigating Arcade's flagship therapeutic game, StarStarter Rx (aka ABM-01) as the first game-based treatment for the most prevalent anxiety condition, Social Anxiety Disorder.
  • Co-Founder and Chief Science Officer of Arcade Therapeutics, Tracy Dennis-Tiwary PhD added, "Only half of those suffering from depression seek and receive treatment.

Akron Children's secures NIH grant to lead research on home-based pediatric palliative care

Retrieved on: 
Tuesday, April 11, 2023
Chromosome, Life, Nationwide Children's Hospital, R01, Rady Children's Hospital, Parent, NINR, COVID-19, DSM-IV codes, Quality of life, Human, Research, Bangladesh Technical Education Board, Science, Hospital, Nursing Research, Texas Children's Hospital, Patient, Cincinnati Children's Hospital Medical Center, Child, Palliative care, Muscular dystrophy, NIH, Caregiver, Nursing, Residential care, Akron Children's Hospital

Dr. Daniel Grossoehme, a senior scientist in Akron Children's Rebecca D. Considine Research Institute, will be the principal investigator.

Key Points: 
  • Dr. Daniel Grossoehme, a senior scientist in Akron Children's Rebecca D. Considine Research Institute, will be the principal investigator.
  • "This type of research grant – the R01 – from the NIH is considered one of the highest in academia, awarded to less than 20 percent of the applicants.
  • According to Dr. Grossoehme, most of the current standards for care for home-based pediatric hospice and palliative care were derived from adult hospice and palliative care, and generally represent the perspectives of parents and providers from data which pre-dates the COVID-19 pandemic.
  • Pediatric palliative care teams offer these children and their families symptom management, decision-making guidance, and spiritual/psychosocial care.

Brooks Rehabilitation and University of Utah Researchers Receive $1.6 million Grant to Study Mindfulness in Physical Therapy for Chronic Pain and Opioid Usage

Retrieved on: 
Thursday, February 9, 2023
R01, NCCIH, Doctor of Science, Mogul skiing, Attention, DPT, University, Physician, Drug, Alternative medicine, Patient, Bangladesh Technical Education Board, Thought, NIH, Pain, Rehabilitation, Florida College, Chronic pain, Mindfulness, PT, Therapy, University of Florida College of Public Health and Health Professions, CSCS, Pain management, Anxiety, Physical, Death, National Center for Complementary and Integrative Health, Public health, Exercise, MPH, COVID-19, UF, Doctor of Philosophy, Dentistry, Nursing

ORLANDO, Fla. and JACKSONVILLE, Fla., Feb. 9, 2023 /PRNewswire/ -- One third of adults in the U.S. have chronic musculoskeletal pain. Opioids are commonly prescribed for pain management, however prescription opioids can pose risks of opioid misuse, addiction, overdose and even death. Physical therapy is a non-pharmacological approach that can help mitigate these risks, and researchers from Brooks Rehabilitation and the University of Utah believe mindfulness training could be a key addition to a physical therapist's toolkit.

Key Points: 
  • Physical therapy is a non-pharmacological approach that can help mitigate these risks, and researchers from Brooks Rehabilitation and the University of Utah believe mindfulness training could be a key addition to a physical therapist's toolkit.
  • The grant funds a feasibility study to train physical therapists to use mindfulness-based interventions to manage patients with chronic musculoskeletal pain and long-term opioid use.
  • The three-year, multi-site study, "Physical Therapy Integrated with Mindfulness for Patients with Chronic Musculoskeletal Pain and Long-term Opioid Treatment," combines faculty expertise from the University of Utah and UF with the robust rehabilitation system of Brooks Rehabilitation.
  • Results from the study will further support future projects, including testing the effectiveness of integrating mindfulness in the physical therapy setting.

Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor

Retrieved on: 
Tuesday, October 18, 2022
Other Health, Oncology, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Cardiology, Biotechnology, FDA, Health, LinkedIn, SMR, PI, P50, Weill Cornell Medical Center, Medicine, University, UPMC Hillman Cancer Center, EMA, SITC, Memorial, R01, ASCO, Drug development, FACP, Patient, UM1, Twitter, Immunotherapy, Inflammation, Internal medicine, Solution, Trial of the century, AACR, MD, Board, Large, Safety, University of Pittsburgh Medical Center, Associate, Melanoma, Radiation, UPMC, Director, Oncology, Clinical trial, Boston Medical Center, FDA, Empathy, Biomarker, Medical imaging, Pharmaceutical industry

physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the companys Medical Advisory Board.

Key Points: 
  • physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the companys Medical Advisory Board.
  • Dr. Luke brings extensive immuno-oncology expertise to physIQ that will provide immeasurable insight into our work on inflammation and oncology treatments, said Steve Steinhubl, MD, physIQs Chief Medical Officer.
  • Dr. Luke received his medical degree from Rosalind Franklin University of Medicine and Science/Chicago Medical School in North Chicago.
  • He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York.

Children's Cancer Research Fund (CCRF) Awards $100,000 Grants to Eight Early-Career Researchers as Childhood Cancer Awareness Month Wraps

Retrieved on: 
Wednesday, September 28, 2022
Israel Cancer Research Fund, University of Rochester, R01, National, Nationwide Children's Hospital, Children's Cancer Research Fund, Gastrointestinal tract, Safety, Virginia Tech, Incidence, Master of Science, University of Minnesota, Disease, Hospital, SMARCAL1, Seattle Children's, Ewing's sarcoma, Obesity, Lutetium (177Lu) oxodotreotide, Government, Benaroya Research Institute, Clinical trial, Cancer, Acute myeloid leukemia, Doctor of Philosophy, Acute lymphoblastic leukemia, Research, University, Research institute, Dana–Farber Cancer Institute, CCRF, Pharmaceutical industry, Medical imaging, Antibiotics, Dietary supplement, MD

MINNEAPOLIS, Sept. 28, 2022 /PRNewswire/ -- Children's Cancer Research Fund (CCRF) recently awarded these eight promising scientists the Emerging Scientist Award, each worth $100,000, to pursue their research in the childhood cancer field:

Key Points: 
  • Emily Heikamp, MD, PhD, MSc, Dana-Farber Cancer Institute, will research the mechanisms that drive NUP98-r acute myeloid leukemia.
  • Jemma Larson, PhD, University of Minnesota, aims to understand the deadly impact of acute Graft-versus-Host Disease in the gastrointestinal tract.
  • At CCRF, we believe scientists early in their careers have inventive approaches that can advance the childhood cancer research field.
  • Since 1981, CCRF donors have funded research that has revolutionized the way childhood cancer is treated worldwide.

Children's Cancer Research Fund (CCRF) Grants New Local Researchers Emerging Scientist Awards

Retrieved on: 
Wednesday, September 7, 2022
Degenerative disease, National, University, Cancer, Obesity, Research, Government, Doctor of Philosophy, Incidence, Parent, Acute lymphoblastic leukemia, Ewing's sarcoma, CCRF, R01, Pharmaceutical industry

MINNEAPOLIS, Sept. 7, 2022 /PRNewswire/ -- CCRF recently awarded two promising scientists the Emerging Scientist Award at the University of Minnesota. Each award is worth $100,000 and will be used over a one-year period.

Key Points: 
  • CCRF's Emerging Scientist Award develops the independent research of highly qualified scientists still early in their careers.
  • MINNEAPOLIS, Sept. 7, 2022 /PRNewswire/ -- CCRF recently awarded two promising scientists the Emerging Scientist Award at the University of Minnesota.
  • With our Emerging Scientist Award, their ideas turn into mature projects that can vie for larger grants.
  • The Emerging Scientist Award got the ball rolling, and we got it to snowball into a bigger project."